Treats Attention Deficit Hyperactivity Disorder (ADHD). ANDA 205105, held by Impax Laboratories. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 205105 (Methylphenidate Hydrochloride), held by Impax Laboratories, was first approved by FDA on Jul 28, 2016, with 5 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age. Limitations of Use The use of methylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g. weight loss) than patients 6 years and older at the same dosage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 28, 2016 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride10MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride30MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride40MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride50MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride60MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Apr 21, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 21, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jul 28, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters